Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Golden Cariboo (CSE:GCC) (OTC:GCCFF) Expands Gold Footprint in BC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Keros Therapeutics Inc KROS

Biotechnology
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company’s lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or... see more

Current News (NDAQ:KROS)

Keros Therapeutics Announces Final Results of Tender Offer

GlobeNewswire November 20, 2025

Keros Therapeutics Announces Preliminary Results of Tender Offer

GlobeNewswire November 19, 2025

Keros Therapeutics Reports Third Quarter 2025 Financial Results

GlobeNewswire November 5, 2025

Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares

GlobeNewswire October 20, 2025

Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital

GlobeNewswire October 15, 2025

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

GlobeNewswire September 8, 2025

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

GlobeNewswire August 28, 2025

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

PR Newswire August 21, 2025

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire August 20, 2025
View More News ››

Opinion & Analysis (NDAQ:KROS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:KROS)

Keros Therapeutics, Inc. (KROS): Pioneering TGF-β Targeted T

Looks like KROS is making some serious moves in the TGF-β space. Phase 2 data for elritercept in MDS looking promising with transfusion...
MikeTester - January 24, 2025

Watching and waiting to see

Which direction this stock is going to go after the company made some bad news announcement the other day.It is on my watchlist now after...
coolfooldumbguy - December 13, 2024
View more Bullboard ››

Pinnacle Silver and Gold Corp

Pinnacle Silver and Gold Corp

Pinnacle Silver and Gold Corp., an exploration stage company, engages in the acquisition and exploration of mineral ...
View More »

Podcasts